Jeffrey Epstein had documented interest in biotechnology, life extension, and what might broadly be called transhumanist science — the frontier where medicine, genetics, and technology intersect to extend human capability and lifespan. This interest appeared in both his philanthropy and his investment activities.
Documented investments:
Epstein made investments in biotech-related companies, though the full scope of his portfolio remains incompletely public. His financial disclosures in 2019 bail proceedings mentioned business interests and financial accounts but did not provide complete investment detail.
The cryonics ambition:
One of the most unusual reported aspects of Epstein’s life-extension interest was his alleged ambition to have his body cryonically preserved after death (or to have his head preserved separately) and to have his DNA preserved for future use in human reproduction. New York Times reporting in 2019 cited contacts who described Epstein expressing these plans. The cryonics plan was not executed — his body was cremated.
Life extension interest:
Epstein funded and attended discussions on aging, life extension, and related sciences. His patronage of the Santa Fe Institute gave him access to scientists working on complexity theory and biological systems questions relevant to aging.
The eugenics intersection:
Epstein’s investment interest in biotechnology overlapped with his documented views on eugenics — he reportedly expressed interest in “seeding the human race” with his own DNA through hired surrogates. This view positioned biotechnology as a vehicle for genetic selection, the same conceptual space as eugenics.
What happened to biotech investments after death:
Investments and business interests held by Epstein’s estate were subject to the estate proceedings. Specific biotechnology investments and their ultimate disposition have not been fully publicly reported.